Cell and Gene Therapy Logistics: Protecting Viability and Identity

Cell and Gene Therapy Logistics: Protecting Viability and Identity

Cell and gene therapy logistics is different from ordinary cold-chain movement because the shipment can be connected to a patient, donor, manufacturing slot, or treatment schedule. Viability and identity both matter.

The logistics plan must therefore protect the biological condition of the material while keeping a defensible chain of identity and chain of custody. This article explains the controls that advanced therapy teams should consider before dispatch.

What CGT logistics must protect

A cell or gene therapy shipment may involve starting material, drug product, viral vectors, cell banks, or patient-linked specimens. The approved temperature range and handling instructions must come from the program, manufacturer, sponsor, or validated process.

Identity is as important as temperature. Patient ID, donor ID, batch ID, shipper serial number, logger serial number, and handover record should stay connected throughout the journey.

Why chain of identity matters

For autologous or patient-linked workflows, a mismatch is not a routine admin error. It can interrupt manufacturing, delay therapy, or trigger a major investigation.

Chain of identity should be designed into labels, manifests, digital records, handover forms, and receipt checks. It should not rely on memory or informal messages.

Key risks in advanced therapy movement

Risks include dry shipper preparation errors, missing seals, incomplete manifests, unclear custody transfer, logger failure, route delay, customs questions, and receiving-site readiness gaps.

Another risk is treating cryogenic logistics as simply 'very cold shipping'. CGT movement needs procedure, visibility, trained handling, and escalation control.

Best practices for CGT teams

Confirm the chain-of-custody map before dispatch. Define who releases the material, who seals the shipper, who receives the handover, who monitors transit, and who signs at delivery.

Run a pre-shipment readiness call for critical movements. Include the sending site, logistics partner, receiving site, quality representative, and program owner where appropriate.

How Biomed Spedition CryoLink supports CGT logistics

BioMed CryoLink is designed for cryogenic logistics for cell and gene therapy, LN2 dry shipper movement, chain of custody, regulatory support, real-time monitoring, and end-to-end logistics.

For cross-border needs, BioMed Global can support international life-science logistics. BioMed Insured can support high-priority and high-value shipments where insurance support is needed.

Practical checklist

• Identity record: Links patient, donor, batch, shipper, and documents

• Custody handoff: Shows who handled the material and when

• Cryogenic condition: Supports viability during movement

• Real-time visibility: Enables faster action during route changes

• Receipt check: Confirms material, seal, documents, and condition

FAQs

What is chain of identity?

It is the record that links the biological material to the correct patient, donor, batch, or program identity throughout the workflow.

What is chain of custody?

It documents who handled the shipment, when, where, and under what condition.

Does every CGT shipment need cryogenic logistics?

No. Requirements depend on the material and approved handling instructions. Many sensitive workflows do require cryogenic or ultra-low controls.

Why use a specialist partner?

CGT logistics involves identity, custody, temperature, timing, and exception controls that standard transport may not support.

What must be reviewed before publishing this article?

Any claims about ATMP, regulatory support, dry shipper performance, and clinical workflow should be reviewed by Biomed Spedition and cited where needed.

CTA

Need reliable cold-chain logistics for biological samples, pharma shipments, clinical trial materials, or cell and gene therapy logistics? Contact Biomed Spedition for science-led, temperature-controlled logistics support.